Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Breast Neoplasms 4Rectal Neoplasms 3Colorectal Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumor, Pleural 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Malignant Tumor of Ill-defined Site 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Cisplatin 28Pemetrexed 22Gemcitabine 10Nivolumab 9Carboplatin 9pembrolizumab 8tremelimumab 5durvalumab 5atezolizumab 5Radiotherapy 5Doxorubicin 4Chemotherapy, Adjuvant 4Vinorelbine 3Ipilimumab 3Bortezomib 3Bevacizumab 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2sodium thiosulfate 2sargramostim 2niraparib 2nintedanib 2liposomal doxorubicin 2lenvatinib 2defactinib 2cemiplimab 2cediranib 2amatuximab 2Trabectedin 2Neoadjuvant Therapy 2Mitomycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mesothelioma, Malignant × Pharmacogenomic Testing × Clear all
NCT02399371 2026-05-08

Pembrolizumab in Treating Patients With Malignant Mesothelioma

University of Chicago

Phase 2 Completed
65 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡